论文部分内容阅读
目的探讨HBIG阻断乙肝病毒母婴传播临床效果。方法选取我院乙肝病毒携带者孕妇所生婴儿83例,随机分为两组,全程预防组42例作为研究组,未全程预防组41例作为对照组。结果研究组出生脐血抗-HBS检出率90%,较对照组抗-HBS检出率68.42%高,有显著性差异(P<0.05),而研究组中抗-HBS(>10mIU/ml)5%与对照组中(>10mIU/ml)2.63%无显著性差异。结论HBIG全程预防作为阻断乙肝母婴传播,起到降低宫内感染率。
Objective To investigate the clinical effect of HBIG in blocking mother-to-child transmission of hepatitis B virus. Methods Eighty-three infants born to hepatitis B virus carriers in our hospital were randomly divided into two groups. The whole prevention group (n = 42) served as the study group, and the non-prevention group (n = 41) served as the control group. Results The detection rate of anti-HBS in umbilical cord blood of the study group was 90%, which was significantly higher than that of the control group (68.42%) (P <0.05), while the anti-HBS (> 10mIU / ) 5% and control group (> 10mIU / ml) 2.63% no significant difference. Conclusion HBIG whole-course prevention can block the transmission of mother-to-infant hepatitis B and reduce the intrauterine infection rate.